Esophageal cancer drugs are extensively used in the treatment of esophageal adenocarcinoma, squamous cell carcinoma, and others types. More men are affected by esophageal cancer than women. Esophageal cancer is mostly observed in low-income countries. For instance, according to World Cancer Research Fund (WCRF) International report of 2018, highest rate of esophageal cancer was found to be in Malawi, Mongolia, Kenya, and Bangladesh. Treatments such as chemotherapy, immunotherapy, and targeted drug therapies are available for esophageal cancer. Some drugs are used in combinations and are approved by the Food and Drug Administration (FDA) such as XELIRI combinations of Capecitabine and Irinotecan Hydrochloride.
The global esophageal cancer drugs market size was valued at US$ 765.2 million in 2018 and is expected to witness a CAGR of 8.2% over the forecast period (2019 – 2027).
Global Esophageal Cancer Drugs Market Share (%) Analysis, By Therapy Type, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing research & development and increasing prevalence of achalasia is expected to drive growth of the esophageal cancer drugs market
Increasing research and development and launches of novel products by key players are major factors that are expected to drive growth of the global esophageal cancer drugs market in the near future. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to significantly drive growth of esophageal cancer drugs market size. For instance, in February 2019, researchers at Case Western Reserve University, U.S. found that by blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma (EAC), the most common esophageal malignancy in the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.
Furthermore, the major risk factors that leads to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors are expected to increase demand for esophageal cancer drugs over the forecast period. For instance, according to a study published in National Center for Biotechnology Information in 2017, achalasia patients have 50 times higher risk of incidence of esophageal squamous cell carcinoma than the general population. The overall prevalence of achalasia is 9 to 10 in 100,000 people annually, worldwide.
Esophageal Cancer Drugs Market - Restraints
However, high cost of therapy for the treatment of esophageal cancer is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 per year for the treatment and medications while in 1995, the cost was US$ 54,100 per year.
Moreover, the side effects caused by esophageal cancer drugs are loss of appetite and weight loss, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (deep vein thrombosis), nervous system damage, and heart damage. According to the 2017 report of the American Cancer Society (ACS), side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.
Esophageal Cancer Drugs Market - Regional Insights
On the basis of region, the global esophageal cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global esophageal cancer drugs market during the forecast period, owing to high prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.
Asia Pacific is expected to witness rapid growth in the esophageal cancer drugs market during the forecast period, owing to rise in clinical trials conducted in Asian countries for novel drugs to treat esophageal cancer. For instance, National Cancer Center Hospital, Tokyo started a clinical trial in December 2018, which evaluated the comparative study between combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus.
Global Esophageal Cancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Esophageal Cancer Drugs Market - Competitive Landscape
Key players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.
Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.
However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients